New prECision thErapieS for uveal melanoma (targeting the Gαq/GNAQ oncogenic Signaling cIrcuiTrY)

Project Information

NECESSITY

Grant agreement ID: 101027731

DOI

10.3030/101027731

Project closed

EC signature date 16 April 2021

Start date 1 January 2022

End date 31 December 2024

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 269 002,56

EU contribution

€ 269 002,56

Coordinated by

UNIVERSITA DI PISA
Italy

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry

Author(s): Nadia Arang, Simone Lubrano, Damiano Cosimo Rigiracciolo, Daniela Nachmanson, Scott M Lippman, Prashant Mali, Olivier Harismendy, J Silvio Gutkind
Published in: Journal of Biological Chemistry, Issue 2023 Feb, 2023, Page(s) 299(2):102866, ISSN 1083-351X
Publisher: Elsevier
DOI: 10.1016/j.jbc.2022.102866

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Author(s): Nadia Arang, Simone Lubrano, Michele Ceribelli, Damiano C Rigiracciolo, Robert Saddawi-Konefka, Farhoud Faraji, Sydney I Ramirez, Daehwan Kim, Frances A Tosto, Erica Stevenson, Yuan Zhou, Zhiyong Wang, Julius Bogomolovas, Alfredo A Molinolo, Danielle L Swaney, Nevan J Krogan, Jing Yang, Silvia Coma, Jonathan A Pachter, Andrew E Aplin, Dario R Alessi, Craig J Thomas, J Silvio Gutkind
Published in: Cell Reports Medicine, Issue 2023 Nov 21, 2023, Page(s) 4(11):101244, ISSN 2666-3791
Publisher: Elsevier
DOI: 10.1016/j.xcrm.2023.101244